Arabic Arabic English English French French German German
dark

Genentech’s Combo Therapy for Rare Blood Cancers Scores Breakthrough Designation

​Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Digital Health Funding Is Higher Than Ever Before

Next Post

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Related Posts
Total
0
Share